Physician profile
Biljinder S Chima
NPI 1205084910
$15,660.91
in general payments reported to CMS, 2019-2025
65 companies · $2,078 in 2025
The $2,078 reported for 2025 was more than what 95% of Sports Medicine (Family Medicine) providers received nationally (typical 2025 total: $113).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,475 · 2020: $2,220 · 2021: $2,481 · 2022: $2,616 · 2023: $2,500 · 2024: $2,290 · 2025: $2,078.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,819 · Education: $48.58.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,819.32 |
| Education | $48.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,408.04 | 2021-2025 | Ubrelvy, Qulipta, Vraylar |
| Glaxosmithkline, LLC. | $1,759.94 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $1,689.93 | 2019-2025 | Breztri, Airsupra, Fasenra |
| Novo Nordisk INC | $1,040.53 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,016.62 | 2019-2025 | Jardiance, Spiriva Respimat, Synjardy |
| Lilly USA, LLC | $902.83 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $886.18 | 2019-2025 | |
| Amgen INC. | $811.42 | 2019-2025 | Evenity, Repatha, Prolia |
| Allergan, INC. | $362.84 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $348.00 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $291.65 | 2020-2025 | Gardasil 9, Vaxneuvance, Gardasil |
| Astellas Pharma US INC | $269.37 | 2019-2025 | Veozah |
| Kowa Pharmaceuticals America, INC. | $256.82 | 2019-2023 | Seglentis, Livalo |
| Bayer Healthcare Pharmaceuticals INC. | $245.04 | 2021-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $218.11 | 2019-2024 | Xifaxan |
Show all 65 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Biljinder Chima listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.